COVID-19 and Respiratory Failure: A Retrospective Observational Study From a Rural Midwest Hospital.

Autor:	Kneller A; Medicine, Kansas City University, Joplin, USA., Abadir C; Medicine, Kansas City University, Joplin, USA., Amadasu O; Medicine, Kansas City University, Joplin, USA., Matias M; Medicine, Kansas City University, Joplin, USA., Arnce RD; Primary Care, Kansas City University, Joplin, USA.; Emergency Medicine, Freeman Health System, Joplin, USA., Beyersdorfer N; Primary Care, Kansas City University, Joplin, USA., Wolff DW; Basic Sciences and Pharmacology, Kansas City University, Joplin, USA., Stahl G; Statistics, Freeman Health System, Joplin, USA., Johnson K; Mathematics, Missouri Southern State University, Joplin, USA., Goade S; Clinical Pharmacy, Freeman Health System, Joplin, USA.; Medicine, Kansas City University, Joplin, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Oct 24; Vol. 15 (10), pp. e47593. Date of Electronic Publication: 2023 Oct 24 (Print Publication: 2023).
DOI:	10.7759/cureus.47593
Abstrakt:	Background Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produces the coronavirus disease of 2019 (COVID-19), primarily presenting with respiratory symptoms, including cough, shortness of breath, etc. Respiratory failure can present similarly to a COVID-19 infection, and COVID-19 infection can cause respiratory failure. Thus, it is important to study respiratory failure, COVID-19, and the interaction between the two in hopes of improving patient outcomes. In this study, we compared mortality rates in patients admitted with COVID-19, respiratory failure, or both. Mortality rates in our study populations were further scrutinized based on patient age. Materials and methods Respiratory failure and COVID-19 data were collected via the electronic medical records system at Freeman Health System, a 410-bed, rural hospital, in Neosho and Joplin, Missouri, from April 2020 through December 2021. The patient population included all patients admitted to the hospital with a diagnosis of COVID-19 or respiratory failure, as defined by the International Classification of Disease, Tenth Revision (ICD-10). Patients with or without COVID-19, with or without respiratory failure, and patients with respiratory failure with COVID-19 were included. Results There was a significant increase in mortality (17.28%) in patients with COVID-19 and respiratory failure (P1) compared to patients with COVID-19 who did not have respiratory failure (P2). No significance was found when comparing patients with COVID-19 and respiratory failure (P1) and patients with respiratory failure without COVID-19 (P3) (p value=0.4921). In contrast, when divided based on age, we found a significant increase in mortality in patients 65 and older with COVID-19 and respiratory failure compared to patients 65 and older with respiratory failure who did not have COVID-19 (P5). There were no significant mortality increases in other comparisons. Conclusion When comparing patient populations within the Freeman Health System, patients with COVID-19 and respiratory failure had similar mortality rates as those with respiratory failure without COVID-19, while patients with only COVID-19 had a markedly reduced mortality rate, relatively. The higher mortality rates in patients with only respiratory failure when compared to patients with both respiratory failure and COVID-19 indicate that the presence of respiratory failure likely plays a bigger role in the inflammatory response that reduces one's chance of survival in this setting. Furthermore, age was shown to be a significant risk factor as patients aged 65 and older showed a greater mortality rate when patients had both COVID-19 and respiratory failure compared to patients with both conditions below the age of 65. The decrease in immune response that results in older patients is likely the largest contributing factor along with the increased likelihood of patients in this population also having more comorbidities, further decreasing the chance of survival. Future studies can investigate alternate treatment plans for patients aged 65 and older who are at higher risk of mortality with COVID-19 and respiratory failure. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Kneller et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu